High Point, North Carolina — According to state and local economic development sources Cambrex plans to invest $30,000,000.00 to build out new space in High Point. The company plans to occupy the new space at 4180 Mendenhall Oaks Pkwy in High Point, on or about June 1, 2022. According to the company website Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market. With over 40 years experience and a growing team of over 2,100 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing. Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

To learn more about Cambrex, visit https://www.cambrex.com/

Company Contact:
Thomas Loewald, Chief Executive Officer
thomas.loewald@cambrex.com
https://www.linkedin.com/in/thomas-loewald-ba81296/
201-804-3000

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved